Trump’s Drug Pricing Deals Are a Farce
WASHINGTON, D.C. – President Donald Trump is expected to announce more most-favored nation (MFN) drug pricing deals with additional pharmaceutical companies today. Public Citizen plans to immediately file a Freedom of Information request to obtain the texts of the newly claimed White House deals. Peter Maybarduk, Access to Medicines director for Public Citizen, issued the following statement:
“It has been nearly a year since Trump announced his first secret MFN deal with Pfizer, and he has almost nothing to show for it. The new deals are a distraction from the administration’s failed plan to lower U.S. drug prices to the levels paid in other wealthy countries. A more serious approach would build international reference pricing into Medicare drug price negotiation. Instead, Trump is cozying up to Big Pharma and keeping American drug prices high.
“There still is no evidence that any pharma company has followed through on prior commitments to the Trump administration to launch new drugs at MFN-price points. Uptake of TrumpRx, which may cause consumers to overpay on medicines, has been lackluster. The Centers for Medicare and Medicaid Services (CMS) has not announced any state participants in a pilot to test MFN-based prices in Medicaid. And CMS has failed to issue final rules to test MFN-pricing in Medicare, while simultaneously excluding almost all drug companies from these programs.”